Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid
leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of
relapse in patients with acute myeloid leukemia in remission.
PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus
histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in
remission following previous therapy.